Sign In
Buy VRNA
$106.91
+0 (+0%)
At Close: Jan 06, 2026
New Strong Buy Stocks for July 14th
06:59am, Thursday, 14'th Jul 2022
CHMG, CQP, VRNA, JBI and SYY have been added to the Zacks Rank #1 (Strong Buy) List on July 14, 2022.
Verona Pharma to Present at Jefferies Healthcare Conference
02:00am, Wednesday, 25'th May 2022
LONDON and RALEIGH, N.C., May 25, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces that Chris Martin, Senior Vice President of Commercial, will present a comp
Abstract supports ongoing Phase 3 program and planned NDA submission Abstract supports ongoing Phase 3 program and planned NDA submission
Verona Pharma Announces May 2022 Investor Conference Participation
02:00am, Wednesday, 04'th May 2022
LONDON and RALEIGH, N.C., May 04, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces the company will participate in the following conferences in May 2022:
Verona Pharma to Report First Quarter 2022 Financial Results and Provide Corporate Update
02:00am, Tuesday, 19'th Apr 2022
LONDON and RALEIGH, N.C., April 19, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announc
Verona Pharma plc 2021 Q4 - Results - Earnings Call Presentation
07:42pm, Friday, 04'th Mar 2022 Seeking Alpha
Verona Pharma plc (VRNA) CEO David Zaccardelli on Q4 2021 Results - Earnings Call Transcript
08:33pm, Thursday, 03'rd Mar 2022 Seeking AlphaVerona Pharma plc (VRNA) CEO David Zaccardelli on Q4 2021 Results - Earnings Call Transcript
03:33pm, Thursday, 03'rd Mar 2022
Verona Pharma plc (VRNA) CEO David Zaccardelli on Q4 2021 Results - Earnings Call Transcript
Verona Pharma: Q4 Earnings Insights
01:10pm, Thursday, 03'rd Mar 2022 Benzinga
Verona Pharma (NASDAQ: VRNA ) reported its Q4 earnings results on Thursday, March 3, 2022 at 08:00 AM. Here''s what investors need to know about the announcement. Earnings Verona Pharma beat estimated earnings by 16.67%, reporting … Full story available on Benzinga.com
Verona Pharma ADR Earnings Beat, Revenue Inline In Q1 By Investing.com
11:37am, Thursday, 03'rd Mar 2022 Investing.com
Verona Pharma ADR Earnings Beat, Revenue Inline In Q1
Verona Pharma GAAP EPS of -$0.05 beats by $0.30
07:52am, Thursday, 03'rd Mar 2022 Seeking Alpha
Verona Pharma press release (VRNA): Q4 GAAP EPS of -$0.05 beats by $0.30.Cash and cash equivalents at December 31, 2021, were $148.4 M (December 31, 2020: $188.0M)
Verona Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
07:00am, Thursday, 03'rd Mar 2022 GlobeNewswire
Phase 3 ENHANCE program on track to report top-line COPD data in 2022
Verona Pharma to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update
07:00am, Thursday, 17'th Feb 2022 GlobeNewswire
LONDON and RALEIGH, N.C., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the fourth quarter and full year ended December 31, 2021 on Thursday, March 3, 2022 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update.
Verona Pharma to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update
02:00am, Thursday, 17'th Feb 2022
LONDON and RALEIGH, N.C., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announce
